Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy

NCT07243899 · clinicaltrials.gov ↗

COMPLETED

Status

3000

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

OTHER: This study is an observational study; the intervention is not applicable.

Sponsor

Shanghai Zhongshan Hospital